## Marek Minarik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2689451/publications.pdf

Version: 2024-02-01

106 papers

1,499 citations

279798 23 h-index 330143 37 g-index

108 all docs 108 docs citations

108 times ranked 2567 citing authors

#	Article	IF	CITATIONS
1	Toward Male Individualization with Rapidly Mutating Y-Chromosomal Short Tandem Repeats. Human Mutation, 2014, 35, 1021-1032.	2.5	151
2	Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World Journal of Gastroenterology, 2007, 13, 3714.	3.3	95
3	Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Analytical Biochemistry, 2013, 433, 227-234.	2.4	90
4	Molecular biology of pancreatic cancer. World Journal of Gastroenterology, 2011, 17, 2897.	3.3	69
5	Fraction collection in micropreparative capillary zone electrophoresis and capillary isoelectric focusing. Electrophoresis, 2000, 21, 247-254.	2.4	65
6	The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growthÂfactor receptor tyrosine kinase inhibitors in non–small cellÂlung cancer. Cancer Genetics, 2013, 206, 26-31.	0.4	56
7	Colorectal cancer screening: 20 years of development and recent progress. World Journal of Gastroenterology, 2014, 20, 3825.	3.3	53
8	Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Research, 2010, 30, 1667-71.	1.1	50
9	The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review ofÂthe literature. Gastrointestinal Endoscopy, 2016, 84, 718-725.	1.0	46
10	Ultrafast DNA analysis by capillary electrophoresis/laser-induced fluorescence detection. Electrophoresis, 1998, 19, 1436-1444.	2.4	42
11	Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma, 2016, 63, 471-476.	1.6	40
12	Dispersion effects accompanying pressurized zone mobilisation in capillary isoelectric focusing of proteins. Journal of Chromatography A, 1996, 738, 123-128.	3.7	34
13	Automated High-Throughput Infusion ESI-MS with Direct Coupling to a Microtiter Plate. Analytical Chemistry, 2001, 73, 1449-1454.	6.5	31
14	Design of a fraction collector for capillary array electrophoresis. Electrophoresis, 2002, 23, 35.	2.4	31
15	MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterology Research and Practice, 2015, 2015, 1-11.	1.5	30
16	Somatic <i>TP53</i> mutation mosaicism in a patient with Li–Fraumeni syndrome. American Journal of Medical Genetics, Part A, 2009, 149A, 206-211.	1.2	29
17	Colorectal cancer prevention in the Czech Republic. European Journal of Cancer Prevention, 2014, 23, 18-26.	1.3	29
18	Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumor Biology, 2015, 36, 5801-5805.	1.8	29

#	Article	IF	CITATIONS
19	Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Research, 2009, 29, 1803-10.	1.1	28
20	Cycling gradient capillary electrophoresis: A low-cost tool for high-throughput analysis of genetic variations. Electrophoresis, 2003, 24, 1716-1722.	2.4	27
21	Assembly of a large Y-STR haplotype database for the Czech population and investigation of its substructure. Forensic Science International: Genetics, 2010, 4, e75-e78.	3.1	26
22	Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response. Frontiers in Oncology, 2020, 10, 1028.	2.8	25
23	Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Research, 2009, 29, 2767-73.	1.1	25
24	Mutation Detection in KRAS Exon 1 by Constant Denaturant Capillary Electrophoresis in 96 Parallel Capillaries. Analytical Biochemistry, 2002, 304, 200-205.	2.4	24
25	Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA. World Journal of Gastroenterology, 2019, 25, 6939-6948.	3.3	24
26	Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Research, 2013, 33, 1705-11.	1.1	24
27	Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy. Acta Cardiologica, 2012, 67, 23-29.	0.9	22
28	Application of high-resolution capillary array electrophoresis with automated fraction collection for GeneCallingâ,,¢ analysis of the yeast genomic DNA. Electrophoresis, 2003, 24, 639-647.	2.4	21
29	Size-based separation of polyelectrolytes by capillary zone electrophoresis: Migration regimes and selectivity of poly(styrenesulphonates) in solutions of derivatized cellulose. Electrophoresis, 1997, 18, 98-103.	2.4	20
30	Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. Neoplasma, 2012, 60, 26-32.	1.6	20
31	Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. Anticancer Research, 2012, 32, 1621-6.	1.1	18
32	High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. Tumor Biology, 2015, 36, 9215-9222.	1.8	17
33	Evaluation of denaturing conditions in analysis of DNA variants applied to multi-capillary electrophoresis instruments. Journal of Separation Science, 2003, 26, 1163-1168.	2.5	16
34	Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research, 2016, 36, 2459-65.	1.1	13
35	Application of cycling gradient capillary electrophoresis to detection of APC, K-ras, and DCC point mutations in patients with sporadic colorectal tumors. Electrophoresis, 2004, 25, 1016-1021.	2.4	12
36	Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Letters, 2006, 242, 68-76.	7.2	12

#	Article	IF	CITATIONS
37	Multicapillary electrophoresis of unlabeled DNA fragments with high-sensitive laser-induced fluorescence detection by counter-current migration of intercalation dye. Electrophoresis, 2005, 26, 4064-4069.	2.4	11
38	Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery. Advances in Clinical and Experimental Medicine, 2016, 25, 1273-1279.	1.4	11
39	Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. Anticancer Research, 2017, 37, 6469-6476.	1.1	11
40	A novel highâ€resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA. Electrophoresis, 2010, 31, 3518-3524.	2.4	10
41	Rapid testing of clopidogrel resistance by genotyping of <scp>CYP2C19</scp> and <scp>CYP2C9</scp> polymorphisms using denaturing onâ€chip capillary electrophoresis. Electrophoresis, 2012, 33, 1306-1310.	2.4	9
42	Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. Anticancer Research, 2016, 36, 455-60.	1.1	9
43	Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy. Journal of Separation Science, 2010, 33, 2349-2355.	2.5	8
44	Second line treatment in advanced non-small cell lung cancer (NSCLC): Comparison of efficacy of Erlotinib and chemotherapy. Neoplasma, 2012, 60, 129-134.	1.6	8
45	Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC. Neoplasma, 2013, 60, 425-431.	1.6	8
46	Prognostic Importance of Cell Cycle Regulators Cyclin D1 ( <i>CCND1</i> ) and Cyclin-Dependent Kinase Inhibitor 1B ( <i>CDKN1B</i> /p27) in Sporadic Gastric Cancers. Gastroenterology Research and Practice, 2016, 2016, 1-8.	1.5	7
47	Low Prevalence and Variable Clinical Presentation of Troponin I and Troponin T Gene Mutations in Hypertrophic Cardiomyopathy. Genetic Testing and Molecular Biomarkers, 2009, 13, 647-650.	0.7	6
48	Capillary electrophoresis, a method for the determination of nucleic acid ligands covalently attached to quantum dots representing a donor of Förster resonance energy transfer. Journal of Separation Science, 2018, 41, 2961-2968.	2.5	6
49	Longitudinal molecular characterization of endoscopic specimens from colorectal lesions. World Journal of Gastroenterology, 2016, 22, 4936.	3.3	6
50	Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease. Journal of Thrombosis and Thrombolysis, 2013, 36, 1-6.	2.1	5
51	Comparison of Native Aspirates and Cytological Smears Obtained by EUS-Guided Biopsies for Effective DNA/RNA Marker Testing in Pancreatic Cancer. Pathology and Oncology Research, 2020, 26, 379-385.	1.9	5
52	Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors. Journal of Separation Science, 2018, 41, 2819-2827.	2.5	4
53	Combination of Circulating Tumour DNA and sup > 18 / sup > F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study. Cancer Genomics and Proteomics, 2022, 19, 270-281.	2.0	4
54	Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections. Electrophoresis, 2006, 27, 3856-3863.	2.4	3

#	Article	IF	Citations
55	Variants in miRNA Regulating Cardiac Growth Are Not a Common Cause of Hypertrophic Cardiomyopathy. Cardiology, 2015, 130, 137-142.	1.4	3
56	High performance liquid chromatography column efficiency enhancement by zero dead volume recycling and practical approach using park and recycle arrangement. Journal of Chromatography A, 2018, 1554, 1-7.	3.7	3
57	Capillary Electrophoresis and its Basic Principles in Historical Retrospect Part 1. The Early Decades of the "Long Nineteenth Century†The Voltaic Pile, and the Discovery of Electrolysis, Electrophoresis and Electroosmosis. Substantia, 2021, 5, .	0.3	3
58	Erlotinib in the treatment of advanced squamous cell NSCLC. Neoplasma, 2014, 60, 676-682.	1.6	2
59	Highly sensitive quantitative detection of circulating tumor DNA in urine and plasma from advanced colorectal cancer patients in aid of early diagnosis of clinically relevant KRAS mutations Journal of Clinical Oncology, 2015, 33, 654-654.	1.6	2
60	Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. Anticancer Research, 2016, 36, 447-53.	1.1	2
61	Circulating Free Tumor DNA in Patient Plasma is a Near-Perfect Marker for Metastatic Spread of Colorectal Cancer: A Study on 165 Patients Undergoing Surgical Treatment. Gastroenterology, 2011, 140, S-343.	1.3	1
62	Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Lung Cancer, 2012, 77, S30.	2.0	1
63	Retreatment with Erlotinib of a Patient with Metastatic NSCLC Harboring EGFR Mutation: A Case Report. Tumori, 2014, 100, e70-e73.	1.1	1
64	Abstract 4943: Detection of specific KRAS mutation type, Gly12Asp (GGT>GAT), in EUS-guided fine needle aspiration cytology (EUS-FNAC) identifies pancreatic cancer patients with poor prognosis. , 2016, , .		1
65	Current possibilities of predicting the therapeutic response to neoadjuvant chemoradiotherapy in rectal cancer. Gastroenterologie A Hepatologie, 2020, 74, 393-403.	0.1	1
66	Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report. Tumori, 2014, 100, e70-3.	1.1	1
67	D3-01: Genotyping single-nucleotide polymorphisms(SNP) in ERCC1, XPD, XRCC1, XRCC3 and MDR1 and CCND1 genes for response and toxicity prediction in chemotherapy of non small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, S396-S397.	1.1	O
68	P3-131: Mutations of EGFR and k–ras oncogene as predictors of tyrosinkinase inhibitors therapeutic outcome in NSCLC patients. Journal of Thoracic Oncology, 2007, 2, S735.	1.1	0
69	106 A POLYMORPHISM IN 5-ALPHA-REDUCTASE (SRD5A2) GENE SHOWS NOVEL ASSOCIATION WITH PROSTATE CANCER. European Urology Supplements, 2007, 6, 49.	0.1	O
70	9074 POSTER DNA Hypermethylation in Progressive Advanced Non Small Cell Lung Cancer. European Journal of Cancer, 2011, 47, S614.	2.8	0
71	9093 POSTER The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors. European Journal of Cancer, 2011, 47, S620.	2.8	O
72	Su1893 Circulating Free Tumor DNA as a Promising Marker for the Prediction of Survival and Monitoring of Remission in Colorectal Cancer After Radical Surgery. Gastroenterology, 2012, 142, S-529.	1.3	0

#	Article	IF	CITATIONS
73	Options of genetic testing and methylation analysis of circulating free tumor DNA (tumor cell-free) Tj ETQq1	1 0.784314 rg 2.0	BT/Overloc
74	Targeted therapy of EGFR mutated lung adenocarcinoma as neoadjuvant treatment followed lung resectionâ€"Case report. Lung Cancer, 2012, 77, S28.	2.0	0
75	Retreatment with erlotinib in NSCLC harboring EGFR mutationâ€"Case report. Lung Cancer, 2012, 77, S29.	2.0	O
76	EGFR mutations in patients with advanced NSCLC. Lung Cancer, 2012, 77, S30.	2.0	0
77	Su1976 A Molecular Classification of Gastric Cancers by Evaluation of Somatic Mutations and Gene Amplifications. Gastroenterology, 2013, 144, S-522.	1.3	O
78	149 Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patients. European Journal of Cancer, 2014, 50, 51.	2.8	0
79	Sa1386 EUS-Guided Biopsies for Molecular Testing of Pancreatic Cancer: Optimization of Experimental Parameters for DNA and miRNA Extraction and Analysis. Gastroenterology, 2014, 146, S-280.	1.3	O
80	Tu1889 A Long-Term Follow-Up of Patients With Recurring Sporadic Polyps: Is There a Benefit From Mutation Testing of Adenomatous Tissue?. Gastroenterology, 2014, 146, S-864-S-865.	1.3	0
81	Su2005 Prospective Longitudinal Molecular Characterization of Colorectal Tumors Based on CIMP/MSI/BRAF/KRAS Classification: Comparison of Advanced Adenomas to Early and Late Carcinomas. Gastroenterology, 2016, 150, S608.	1.3	0
82	Su2028 KRAS Mutation Assay on EUS FNA Specimens From Pacients With Pancreatic Mass. Gastroenterology, 2016, 150, S615.	1.3	0
83	Nucleic Acids   Chromatographic and Electrophoretic Methods $\hat{a}^{*}\dagger$ . , 2017, , .		O
84	Su1030 – Utility of Targeted Next-Generation Sequencing Panel for Comprehensive Focal Profiling of Dna Mutations in Tissue Samples of Patients with Ibd. Gastroenterology, 2019, 156, S-489.	1.3	0
85	P817 Profiles of somatic mutations in tissue of IBD and IBD-associated carcinomas revealed by a targeted next-generation sequencing (NGS) tumour panel confirm notable differences from sporadic colorectal carcinomas. Journal of Crohn's and Colitis, 2019, 13, S531-S531.	1.3	0
86	Our initial experience with genetic testing of patients with hypertrophic cardiomyopathy: mutations of troponin T and troponin I genes. Cor Et Vasa, 2008, 50, 242-245.	0.1	0
87	Molecular classification of gastric cancers by parallel examination of multiple gene amplifications Journal of Clinical Oncology, 2014, 32, 74-74.	1.6	O
88	Evaluation of circulating-tumor DNA (ctDNA) as a source material for molecular phenotyping of colorectal tumors Journal of Clinical Oncology, 2015, 33, 642-642.	1.6	0
89	Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases. Journal of Clinical Oncology, 2015, 33, 3594-3594.	1.6	O
90	Abstract 5237: Monitoring minimal residual disease by urinary or plasma circulating tumor DNA of KRAS mutation burden in colorectal cancer patients with resectable liver metastases. , 2015, , .		0

#	Article	IF	Citations
91	Abstract 2406: Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers. , $2015,  ,  .$		0
92	Utility of a panel of gene mutations and amplifications for estimation of prognosis in patients with gastric cancer. Gastroenterologie A Hepatologie, 2016, 70, 244-251.	0.1	0
93	Abstract 3139: Liquid biopsy (ctDNA) testing in clinical management of solid cancers: 5-years of experience., 2016,,.		0
94	Abstract A19: Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients. , 2016, , .		0
95	Abstract B18: Molecular cancer testing of KRAS and miR-21 from EUS-guided biopsies of pancreatic tissue: Utility of aspirates vs. cytology. , 2016, , .		0
96	Abstract B09: Molecular phenotyping of colorectal tumors in clinical practice: Assignment of extended prognostic subtypes by direct testing of endoscopic specimens. , 2017, , .		0
97	Abstract B24: The significance of postoperative follow-up of patients with advanced colorectal cancer using circulating tumor DNA: Selected case studies. , 2017, , .		0
98	Validation of the denaturing capillary electrophoresis (DCE) assay for non-invasive liquid biopsy in lung carcinoma: A study of concordance with the cobas EGFR mutation test $v2.$ . Journal of Clinical Oncology, 2017, 35, e23040-e23040.	1.6	0
99	Inflammatory bowel disease and gastrointestinal malignancies – risks, incidence and management. Gastroenterologie A Hepatologie, 2017, 71, 388-393.	0.1	0
100	Abstract 412: Application of a serial liquid biopsy ctDNA assay for monitoring efficacy of anti-angiogenic lung cancer therapy. , 2019, , .		0
101	Abstract 405: Using a ctDNA liquid biopsy assay for post-surgical serial monitoring and early detection of disease progression in advanced colorectal cancer patients. , 2019, , .		0
102	Abstract A30: Dynamics of ctDNA may serve as an early predictor of response to nontargeted chemotherapy of advanced lung cancer patients. , 2020, , .		0
103	Abstract 724: Application of oncoMonitorâ, ¢ ctDNA tracking technology for monitoring of therapy and early detection of recurrence in metastatic colorectal cancer., 2020,,.		0
104	Abstract 412: Application of a serial liquid biopsy ctDNA assay for monitoring efficacy of anti-angiogenic lung cancer therapy. , 2019, , .		0
105	Somatic Mutations in Exon 7 of the TP53 Gene in Index Colorectal Lesions Are Associated with the Early Occurrence of Metachronous Adenoma. Cancers, 2022, 14, 2823.	3.7	0
106	Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis. Pathology and Oncology Research, 0, 28, .	1.9	0